GRIN Therapeutics Inc, a developer of therapies to treat serious neurodevelopmental disorders, announced on Tuesday that it has received Priority Medicine (PRIME) designation for radiprodil from the European Medicines Agency (EMA).
Radiprodil is an investigational, potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B), intended for the treatment of GRIN-related neurodevelopmental disorder (NDD).
This decision follows the recent announcements that radiprodil was awarded Breakthrough Therapy designation for the treatment of seizures associated with GRIN-related NDD with gain-of-function (GoF) mutations and Orphan Drug designation for the treatment of GRIN-related NDD by the US Food and Drug Administration (FDA) in February and March 2025, respectively.
GRIN Therapeutics said that it remains on track to initiate a global pivotal Phase 3 clinical trial for radiprodil for the treatment of GRIN-related NDD in mid-2025.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
4basebio announces award of GMP certification for UK DNA manufacturing facility
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
Oncopeptides secures FDA approval to resume OPD5 clinical development